Survey

Japanese patients among least empowered in the developed world

A new study suggests that Japanese patients with chronic conditions score lower than other developed countries across a range of metrics. Isaac Hanson reports.

Japan’s “paternalistic” health culture may be related to lower patient satisfaction. Credit: Vitalii Stock/Shutterstock

Japanese patients with chronic conditions including cancer, diabetes and MS are significantly less satisfied with care received, and less confident in managing their own symptoms than peers in countries like the US, Germany and France, a new study suggests. 

Globaldata’s Patient Empowerment Thematic Intelligence report surveyed over 500 chronic patients across 11 countries on aspects of their care, catalogued by disease and nationality. 

The general trend of the study was that chronic patients predominantly feel empowered to manage and understand their treatment.  

“The majority of patients with various chronic conditions agreed or strongly agreed that upon diagnosis they were given enough information about their condition, treatment options, medications, and services by their healthcare provider,” GlobalData’s Thematic Intelligence team explains.  

Similarly, around three-quarters of patients studied believe that the data they receive from their health teams is evidence-based, and in all countries but Japan over 70% of patients were happy with the amount and quality of information received about their condition. In Japan, the number only reaches 60%. 

Japan’s outlier status remains visible in more detailed breakdowns of patient empowerment metrics, scoring lowest on polling around informed decision-making, feeling respected by healthcare providers and confidence in managing signs and symptoms of their condition.  

In many cases, the discrepancies are large, as in the case of symptom management in which its 42% agreement is over 20 points below its next closest comparator, Canada.  

This mixture of dissatisfaction and lack of confidence may be explained by culture, the study suggests. “Japanese patients may still have fewer opportunities to participate in medical decision making as a result of the traditional paternalism of Japanese physicians, where HCP decisions are unquestionable and accepted by the patients,” the report explains.  

Whatever the reason, close scrutiny of the matter is necessary to ensure standards of care remain high. 

Go to article: Home | Lula’s progress plan for Brazil: A year onGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: XylemGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: phasetwoGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DepthGo to article: Lula’s progress plan for Brazil: A year on Go to article: How sham patents are hurting the pharma industryGo to article: Tracking the opioid lawsuit settlements amidst calls for oversight Go to article: Cell and gene therapy landscape in the USGo to article: Q&A: Cell and gene therapy value assessments need a rework to allow access Go to article: Pharmaceutical discovery through a gravitational lens Go to article: Thematic Take: ESGGo to article: Thematic Take: contentsGo to article: Foreword: A growing sense of urgency in ESG Go to article: ESG 1.0 is over – get ready for ESG 2.0 Go to article: ESG becomes mandatory: how to prepareGo to article: Theme timeline: the past, present and future of ESG Go to article: Net-zero strategies for the pharma sector Go to article: Leading pharma companies and initiatives in the race for net zeroGo to article: GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses Go to article: 38% of companies lack an ESG strategy – GlobalData survey Go to article: Sustainability challenges in rare disease trials remain, but change is happeningGo to article: ESCMID 2024: The infectious consequences of climate change Go to article: Bring your own device: How patients own tech is being used in clinical trialsGo to article: Can pharma overcome generative AI’s bias problem?Go to article: China-US tensions are spilling into the biotech sector Go to article: Japanese patients among least empowered in the developed worldGo to article: World Air Quality Report: what are the health impacts and where is it worst? Go to article: Why has New Zealand U-turned on the world’s first smoking ban?Go to article: Microplastics in placentas: how serious is the problem? Go to article: Deal activity related to ESG in the pharma industry since 2021Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: CytivaGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue